Search results for "Antibodies."

showing 10 items of 1857 documents

Women's socioeconomic position in ontogeny is associated with improved immune function and lower stress, but not with height

2020

AbstractImmune function, height and resource accumulation comprise important life history traits in humans. Resource availability models arising from life history theory suggest that socioeconomic conditions influence immune function, growth and health status. In this study, we tested whether there are associations between family income during ontogeny, adult height, cortisol level and immune response in women. A hepatitis B vaccine was administered to 66 young Latvian women from different socioeconomic backgrounds, and blood samples were then collected to measure the level of antibodies that the women produced in response to the vaccination. Cortisol levels were measured from plasma sample…

0301 basic medicineAdultHepatitis B vaccineHydrocortisoneOntogenyBiological anthropologyPhysiologylcsh:MedicineBiologyFamily incomeEvolutionary ecologyArticleLife history theory03 medical and health sciencesYoung Adult0302 clinical medicineImmune systemHumansWomenHepatitis B Antibodieslcsh:ScienceSocioeconomic statusMultidisciplinarylcsh:RImmunityLatviaVaccination030104 developmental biologySocial ClassSocioeconomic Factorsbiology.proteinFemalelcsh:QAntibody030217 neurology & neurosurgeryStress PsychologicalCortisol ; Immune function ; Life history theory ; Sexual dimorphism ; Stress
researchProduct

Hepatitis delta virus infection in a large cohort of chronic hepatitis B patients in Ethiopia.

2017

Background Hepatitis D Virus (HDV)-infection is associated with a more severe outcome in patients with chronic hepatitis B (CHB); however, little is known about the presence of HDV in sub-Saharan Africa. We aimed to determine the prevalence of HDV-infection, as well as its clinical, biological and virological characteristics, in a large CHB cohort in Ethiopia. Methods In total, 1267 HIV-negative CHB patients at St. Paul's Hospital Millennium Medical College in Addis Ababa were screened for anti-HDV antibodies using ELISA assays. Confirmed positive samples were further tested for HDV RNA using a consensus commercial real-time RT-PCR assay. HDV genotypes were also determined for RNA positive …

0301 basic medicineAdultLiver CirrhosisMaleCirrhosisAdolescentvirusesEnzyme-Linked Immunosorbent AssayReal-Time Polymerase Chain ReactionVirusSerologyCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineHepatitis B ChronicInterquartile rangeGenotypeMedicineHumansHepatitis AntibodiesPhylogenyHepatologybusiness.industryCoinfectionvirus diseasesbiochemical phenomena metabolism and nutritionMiddle AgedViral Loadmedicine.diseaseVirologyHepatitis D030104 developmental biologyLogistic ModelsCohort030211 gastroenterology & hepatologyFemaleHepatitis D virusEthiopiaHepatitis Delta VirusbusinessViral loadLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Antibodies against Lewis antigens inhibit the binding of human norovirus GII.4 virus-like particles to saliva but not to intestinal Caco-2 cells.

2016

BACKGROUND: Human noroviruses (NoVs) are the main cause of gastroenteritis worldwide. The most commonly detected NoV strains belong to the genetically diverse GII.4 genotype, with new pandemic variants emerging periodically. Despite extensive efforts, NoV investigation has been hampered by the lack of an effective in vitro cell culture system. However, NoV-derived recombinant virus-like particles (VLPs) resembling empty capsids are good surrogates for analysing NoV antigenicity and virus-ligand interactions. NoV VLPs have been reported to bind to histo-blood group antigens (HBGAs). We have analysed the ability of NoV VLPs derived from GI.1 genotype and from three GII.4 genotype variants, GI…

0301 basic medicineAdultMaleSalivaAntigenicitymedicine.drug_classSwinevirusesVirus AttachmentMonoclonal antibodyImmunofluorescenceVirusMicrobiology03 medical and health sciencesLewis Blood Group Antigensfluids and secretionsAntigenstomatognathic systemGII.4 genotypeHisto-blood group antigens (HBGAs)VirologymedicineAnimalsHumansChildSalivaAutoantibodiesbiologymedicine.diagnostic_testResearchMucinNorovirusvirus diseasesEpithelial CellsMiddle AgedVirology3. Good healthVirus-like particles (VLPs)030104 developmental biologyInfectious DiseasesHuman norovirus (NoV)Host-Pathogen Interactionsbiology.proteinReceptors VirusReceptor bindingFemaleAntibodyCaco-2 Cells
researchProduct

Is Italian population protected from Poliovirus? Results of a seroprevalence survey in Florence, Italy

2018

ABSTRACT Objectives: Periodical assessments of population susceptibility to polioviruses (PV) is essential for evaluating population protection and planning appropriate vaccination strategies. The aim of the current work was to assess serological protective titers against all three polioviruses in the general population of Florence. Methods: A convenience sample of 328 sera, collected in 2009 in Florence (Central Italy) was analyzed. Samples were considered protective if neutralizing antibodies were detected at dilutions ≥1:8, according to the WHO protocols. Results: The immune coverage was 75.3%, 69.2% and 46% for PV1, PV2 and PV3, respectively. The protective titers of neutralizing antibo…

0301 basic medicineAdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaIPV vaccine; Italy; OPV vaccine; poliomyelitis; seroprevalence.Adolescent030106 microbiologyPopulationpoliomyelitiImmunologymedicine.disease_causeAntibodies Viral03 medical and health sciencesYoung Adult0302 clinical medicineSeroepidemiologic StudiesEnvironmental healthSurveys and QuestionnairesmedicineSeroprevalenceImmunology and AllergyHumans030212 general & internal medicineeducationChildAgedPharmacologyAged 80 and overeducation.field_of_studyseroprevalencePoliovirusOPV vaccineInfant NewbornInfantMiddle Agedmedicine.diseaseItalian populationPoliomyelitisVaccinationIPV vaccinePoliovirusGeographyItalyChild PreschoolFemaleResearch PaperPoliomyelitisHuman Vaccines & Immunotherapeutics
researchProduct

Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.

2017

Objective:To identify cell-surface antibodies in patients with neuromyotonia and to describe the main clinical implications.Methods:Sera of 3 patients with thymoma-associated neuromyotonia and myasthenia gravis were used to immunoprecipitate and characterize neuronal cell-surface antigens using reported techniques. The clinical significance of antibodies against precipitated proteins was assessed with sera of 98 patients (neuromyotonia 46, myasthenia gravis 52, thymoma 42; 33 of them with overlapping syndromes) and 219 controls (other neurologic diseases, cancer, and healthy volunteers).Results:Immunoprecipitation studies identified 3 targets, including the Netrin-1 receptors DCC (deleted i…

0301 basic medicineAdultMaleThymomaNeuromyotoniaDeleted in Colorectal CancerThymomaCell Adhesion Molecules NeuronalNerve Tissue ProteinsReceptors Cell SurfaceTransfectionArticle03 medical and health sciences0302 clinical medicineAntigenMyasthenia GravismedicineHumansImmunoprecipitationNerve Growth FactorsReceptorMuscle SkeletalNeural Cell Adhesion MoleculesAgedAutoantibodiesbiologybusiness.industryElectromyographyTumor Suppressor ProteinsCalcium-Binding ProteinsAutoantibodyMembrane ProteinsThymus NeoplasmsMiddle AgedNetrin-1medicine.diseaseDCC ReceptorMagnetic Resonance ImagingMyasthenia gravis030104 developmental biologyHEK293 CellsImmunologybiology.proteinFemaleNeurology (clinical)AntibodybusinessNetrin Receptors030217 neurology & neurosurgeryNeurology
researchProduct

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

2017

Background Inhibitory antibodies towards enzyme replacement therapy (ERT) are associated with disease progression and poor outcome in affected male patients with lysosomal disorders such as Fabry disease (FD). However, little is known about the impact of immunosuppressive therapy on ERT inhibition in these patients with FD. Methods In this retrospective study, we investigated the effect of long-term immunosuppression on ERT inhibition in male patients with FD (n = 26) receiving immunosuppressive therapy due to kidney (n = 24) or heart (n = 2) transplantation. Results No ERT-naive transplanted patient (n = 8) developed antibodies within follow-up (80 ±72 months) after ERT initiation. Seven (…

0301 basic medicineAdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentmedicine.medical_treatmentGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineMaintenance therapyInternal medicineInternal MedicineMedicineHumansEnzyme Replacement TherapyRetrospective StudiesKidneybusiness.industrynutritional and metabolic diseasesImmunosuppressionEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseAntibodies NeutralizingKidney TransplantationTacrolimusTransplantation030104 developmental biologymedicine.anatomical_structureImmunologyPrednisoloneFabry DiseaseHeart Transplantationbusiness030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugJournal of internal medicine
researchProduct

Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases

2020

Abstract Background SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to SARS-CoV-2 play a crucial role in determining the clinical course after first infection. Immunological studies have focussed on patients with moderate to severe disease, demonstrating excessive inflammation in tissues and organ damage. We have studied the individual response to SARS-CoV-2 of asympromatic, mild and severe COVID-19 patients in order to investigate the role of innnate and adaptive immunity in determining the clinical course after first infection. Methods To understand the basis of th…

0301 basic medicineAdultMalelcsh:Immunologic diseases. AllergyImmunologyInflammationDiseaseAdaptive Immunitymedicine.disease_causeAntibodies ViralAsymptomaticSeverity of Illness IndexSerology03 medical and health sciences0302 clinical medicineImmune systeminnate and adaptiveimmune responsemedicineHumansImmunology and AllergyantibodiesNK cellOriginal ResearchCoronavirusB cellsbiologybusiness.industrySARS-CoV-2MonocyteSettore BIO/12COVID-19antibodies; B cells; COVID-19; innate and adaptiveimmune response; monocytes; NK cell; SARS-CoV-2Acquired immune systemImmunity InnateImmunoglobulin AKiller Cells Natural030104 developmental biologymedicine.anatomical_structureImmunoglobulin MSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisImmunologybiology.proteinFemalemedicine.symptomAntibodybusinesslcsh:RC581-607monocytes
researchProduct

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

2021

ObjectiveTo evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic.MethodsIn our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).ResultsThree hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09–13.07] weeks). Three months after the last ocrelizumab in…

0301 basic medicineAdultMalemedicine.medical_specialty41Antigens CD19MedizinLogistic regressionAntibodies Monoclonal HumanizedArticle2303 medical and health sciencesDisability Evaluation0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInterquartile rangeInternal medicinemedicineHumansDosingLymphocyte CountPandemicsRetrospective Studies360B-Lymphocytes120business.industryMultiple sclerosisCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyTreatment OutcomeNeurologyCohortOcrelizumabFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugCohort studyNeurology(R) neuroimmunologyneuroinflammation
researchProduct

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

Secukinumab efficacy in the treatment of nail psoriasis: a case series

2018

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis (PsA), and can significantly impair quality of life (QoL). It is typically difficult to treat compared with skin lesions, although several conventional treatment options are available. The aim of this article is to describe our experience in the treatment of nail psoriasis with secukinumab in a case series. Fifteen patients (11 males and 4 females), with moderate-severe plaque psoriasis and nail psoriasis, eligible for systemic therapy, and received secukinumab. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) assessed cutaneous severity. Nail Psoriasis Severity Index (…

0301 basic medicineAdultMalemedicine.medical_specialtyDermatologyNail psoriasisAntibodies Monoclonal HumanizedSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisNail Diseases0302 clinical medicineQuality of lifePsoriasisSeverity of illnessMedicineHumansPsoriasisIn patientPsoriasibusiness.industrysecukinumabfungifood and beveragesAntibodies MonoclonalMiddle Agedmedicine.diseaseNail DiseaseDermatologyhumanities030104 developmental biologyNAPSITreatment OutcomeNail diseasenail psoriasiQuality of LifeSecukinumabFemalebusinessHuman2708
researchProduct